Trademark: DENZOLUTE 2356669
Word
DENZOLUTE
ID
2356669
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
15 May 2023
Registration Date
15 May 2023
Renewal Date
15 May 2033
Service
WRAYS PTY LTD
Goods and Services:
Class 5:
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; all the above being for human use.
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; all the above being for human use.